| ［1］ |
Kaplan FS, Craver R, MacEwen GD, et al. Progressive osseous heteroplasia: a distinct developmental disorder of heterotopic ossification. Two new case reports and follow⁃up of three previously reported cases［J］. J Bone Joint Surg Am, 1994,76（3）:425⁃436.
|
| ［2］ |
Shore EM, Ahn J, Jan de Beur S, et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia［J］. N Engl J Med, 2002,346（2）:99⁃106. doi: 10.1056/NEJMoa011262.
|
| ［3］ |
张筱雁, 王婷婷, 王琳. 进行性骨发育异常三例分析［J］. 中华皮肤科杂志, 2017,50（8）:595⁃598. doi: 10.3760/cma.j.issn.0412⁃4030.2017.08.012.
|
| ［4］ |
Pignolo RJ, Ramaswamy G, Fong JT, et al. Progressive osseous heteroplasia: diagnosis, treatment, and prognosis［J］. Appl Clin Genet, 2015,8:37⁃48. doi: 10.2147/TACG.S51064.
|
| ［5］ |
Bastepe M. GNAS mutations and heterotopic ossification［J］. Bone, 2018,109:80⁃85. doi: 10.1016/j.bone.2017.09.002.
|
| ［6］ |
Elli FM, Barbieri AM, Bordogna P, et al. Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series［J］. Bone, 2013,56（2）:276⁃280. doi: 10.1016/j.bone.2013.06.015.
|
| ［7］ |
吴凤岐, 王理, 邹继珍, 等. 儿童进行性骨发育异常一例GNAS1基因突变及临床特征的研究［J］. 中华儿科杂志, 2012,50（1）:10⁃14. doi: 10.3760/cma.j.issn.0578⁃1310.2012.01. 003.
|
| ［8］ |
Adegbite NS, Xu M, Kaplan FS, et al. Diagnostic and mutational spectrum of progressive osseous heteroplasia （POH） and other forms of GNAS⁃based heterotopic ossification［J］. Am J Med Genet A, 2008,146A（14）:1788⁃1796. doi: 10.1002/ajmg.a.32346.
|
| ［9］ |
Pignolo RJ, Ramaswamy G, Fong JT, et al. Progressive osseous heteroplasia: diagnosis, treatment, and prognosis［J］. Appl Clin Genet, 2015,8:37⁃48. doi: 10.2147/TACG.S51064.
|
| ［10］ |
Lebrun M, Richard N, Abeguilé G, et al. Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans［J］. J Clin Endocrinol Metab, 2010,95（6）:3028⁃3038. doi: 10.1210/jc.2009⁃1451.
|
| ［11］ |
Pacifici M. Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities［J］. Curr Opin Pharmacol, 2018,40:51⁃58. doi: 10.1016/j.coph.2018.03.007.
|
